Publication

Article

CURE

Fall 2007
Volume6
Issue 5

Secondary Sarcomas

Some cancer therapies can increase the risk of secondary cancers such as sarcoma, especially for childhood cancer survivors.

Some treatments used to fight cancer carry an increased risk of developing other cancers later in life. A recent analysis of data from the Childhood Cancer Survivor Study found patients who were successfully treated for childhood cancer develop sarcoma at a rate nine times greater than the general population.

Factors associated with a higher risk of secondary sarcomas include a younger age at diagnosis of the first cancer (survivors diagnosed with their primary cancer between the ages of 1 and 3 had the highest risk); a family history of cancer; treatment with radiation; and chemotherapy with high doses of anthracyclines. The median age in the study for patients diagnosed with secondary sarcoma was 20, and about 70 percent were diagnosed before age 24.

Making a diagnosis of sarcoma can be difficult, and information about cancer risk factors can be of great use to doctors and patients. It’s important for childhood cancer survivors to make their doctors aware of their history to help them stay alert for secondary sarcoma.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Image of man with black hair.
Some patients with relapsed/refractory diffuse large B-cell lymphoma whose disease progressed after CAR-T cell therapy, responded to odronextamab.
Image of woman with brown hair.
Adolescent and Young Adult Cancer Awareness Week sheds light on the financial hardships young cancer survivors face, including debt and limited assistance.
CURE spoke with Dr. William C. Huang about what kind of team may be required to treat a patient with metastatic kidney cancer.
Image of man wearing baseball cap backwards.
Dr. Emre Yekedüz highlighted strategies that may improve patients' quality of life and mitigate treatment-related side effects in renal cell carcinoma.
Dr. Guru Sonpavde emphasized the importance of better understanding how genetic mutations influence the treatment of cancer care, particularly GU cancers.
Dr. Frederick L. Locke sat down with CURE® to discuss treatment with cema-cel in the ALPHA/ALPHA2 studies for relapsed/refractory large B-cell lymphoma.
Related Content